Clinical Trials Logo

High-risk Human Papillomavirus clinical trials

View clinical trials related to High-risk Human Papillomavirus.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04650711 Recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Immunohistochemical Staining of p16 for the Screening of Cervical Cancer

Start date: November 26, 2020
Phase: Phase 2
Study type: Interventional

Cyclin kinase inhibitor P16INK4A has overexpression in cervical cancer, and hence becoming an alternative method for cervical cancer screening. This study is to investigate the clinical value of P16INK4A and high-risk human papillomavirus (hrHPV) detection of cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+). All eligible participants accept P16INK4A testing, with cytology and/or hrHPV assay. P16INK4A immunohistochemical staining is performed on the retained specimens of cytology. The primary endpoint is the diagnostic accuracy of P16INK4A compared with cytology and/or hrHPV status based on histology results. The accuracy analysis includes sensitivity, specificity, negative predictive value and positive predictive value.

NCT ID: NCT04646954 Recruiting - Cervical Cancer Clinical Trials

DNA Methylation Testing for the Screening of Uterine Cervical Lesion

Start date: November 26, 2020
Phase: Phase 3
Study type: Interventional

In our published work, host DNA methylation testing has been proved to be sensitive and specific to cervical intraepithelial neoplasia (CIN) 2 or more severe lesions (CIN2+). Its screening effects are independent of high-risk human papillomavirus (hrHPV) status. Based on the results of training and validation sets of our previous work, we perform this multicenter, prospective cohort study in unselected participants asking for cervical cancer screening in a hospital-based community. All eligible participants accept DNA methylation testing, with cytology and/or hrHPV assay. The primary endpoint is the diagnostic accuracy of DNA methylation compared with cytology and/or hrHPV status based on histology results. The accuracy analysis includes sensitivity, specificity, negative predictive value and positive predictive value.